Grifols (NASDAQ:GRFS) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Grifols (NASDAQ:GRFS) from a buy rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Other analysts have also recently issued research reports about the stock. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Grifols presently has an average rating of “Reduce” and an average target price of $10.00.

Grifols Price Performance

NASDAQ:GRFS opened at $7.37 on Friday. Grifols has a 52 week low of $6.96 and a 52 week high of $9.90. The firm has a market cap of $5.02 billion, a price-to-earnings ratio of 38.79, a P/E/G ratio of 0.27 and a beta of 0.70. The firm’s 50-day simple moving average is $7.66 and its 200 day simple moving average is $7.73. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.81 and a current ratio of 2.37.

Hedge Funds Weigh In On Grifols

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in Grifols by 41.1% in the third quarter. GAMMA Investing LLC now owns 6,588 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,918 shares during the last quarter. Financial Symmetry Inc bought a new position in Grifols during the 3rd quarter worth approximately $73,000. QRG Capital Management Inc. lifted its position in shares of Grifols by 10.6% in the 2nd quarter. QRG Capital Management Inc. now owns 48,218 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 4,604 shares during the period. Tidal Investments LLC lifted its position in shares of Grifols by 9.8% in the 2nd quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock worth $8,730,000 after purchasing an additional 109,612 shares during the period. Finally, Compass Wealth Management LLC bought a new stake in shares of Grifols in the 2nd quarter valued at $108,000.

About Grifols

Grifols SA is a global healthcare company based in Barcelona, Spain, and is listed on Nasdaq under the symbol GRFS. Founded in 1909, the company is primarily focused on developing, manufacturing and supplying plasma-derived medicines and other healthcare products.

Its principal therapies include immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors, which are used to treat immune deficiencies, respiratory disorders, bleeding conditions and other serious diseases. Grifols operates a network of plasma donation centers, mainly in the United States and Europe, to collect the source plasma used in its medicines.

Grifols also provides diagnostic solutions, including instruments and reagents used in blood typing, transfusion medicine and laboratory testing.